Newsroom

News & Media

Prometheus Biosciences Announces FDA Acceptance of IND Application for PRA023 and Commences Dosing in Phase 1a Clinical Study

Prometheus Biosciences Announces $130 Million Financing to Advance Precision Medicines for the Treatment of Inflammatory Bowel Disease

Prometheus Biosciences Appoints Olivier Laurent, Ph.D. as Chief Technology Officer

Prometheus Biosciences Appoints Joseph C. Papa to its Board of Directors

Prometheus Biosciences and Dr. Falk Pharma GmbH Announce Global Collaboration Agreement to Develop and Commercialize a Novel IBD Antibody

Prometheus Biosciences Appoints Keith W. Marshall as Chief Financial Officer

Prometheus Biosciences Appoints Dr. Thierry Dervieux as Chief Development Officer

Prometheus Biosciences, Inc., Enters Into Multi-Target Strategic Collaboration with Takeda to Develop Targeted Therapies for Inflammatory Bowel Disease

Prometheus Biosciences Strengthens Executive Management Team with New Appointments

Precision IBD Announces Next Phase Of Growth: Appoints Mark C. McKenna As President And Chief Executive Officer, Completes Name Change To Prometheus Biosciences, Inc.

In the News

XCONOMY – Prometheus Bio Taps Thierry Dervieux as Chief Development Officer

XCONOMY – Precision IBD Rebrands as Prometheus and Strikes R&D Deal with Takeda

Events & Presentations

Coming Soon

MENU